{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -8.552631, "regularMarketPrice": 2.78, "earningsTimestamp": 1683662716, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.92, "epsForward": -2.69, "epsCurrentYear": -2.75, "priceEpsCurrentYear": -1.0109091, "sharesOutstanding": 86527200, "bookValue": 2.182, "fiftyDayAverage": 3.353, "fiftyDayAverageChange": -0.57299995, "fiftyDayAverageChangePercent": -0.17089173, "twoHundredDayAverage": 4.32855, "twoHundredDayAverageChange": -1.5485499, "twoHundredDayAverageChangePercent": -0.3577526, "marketCap": 240545616, "forwardPE": -1.0334572, "priceToBook": 1.2740605, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.2 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1594706400000, "priceHint": 4, "marketState": "REGULAR", "exchange": "FRA", "shortName": "POSEIDA THERAP.  DL-,0001", "longName": "Poseida Therapeutics, Inc.", "messageBoardId": "finmb_302863260", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.26, "regularMarketTime": 1683875702, "regularMarketDayHigh": 2.78, "regularMarketDayRange": "2.78 - 2.78", "regularMarketDayLow": 2.78, "regularMarketVolume": 267, "regularMarketPreviousClose": 3.04, "bid": 2.54, "ask": 2.64, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 2.78, "averageDailyVolume3Month": 157, "averageDailyVolume10Day": 105, "fiftyTwoWeekLowChange": 1.02, "fiftyTwoWeekLowChangePercent": 0.57954544, "fiftyTwoWeekRange": "1.76 - 202.0", "fiftyTwoWeekHighChange": -199.22, "fiftyTwoWeekHighChangePercent": -0.98623765, "fiftyTwoWeekLow": 1.76, "fiftyTwoWeekHigh": 202.0, "symbol": "2RZ.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9390 Towne Centre Drive", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 779 3100", "website": "https://poseida.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.", "fullTimeEmployees": 314, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark J. Gergen J.D.", "age": 59, "title": "Pres, CEO & Chairman", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 920740, "fmt": "920.74k", "longFmt": "920,740"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 817228, "fmt": "817.23k", "longFmt": "817,228"}}, {"maxAge": 1, "name": "Mr. Harry J. Leonhardt Esq., J.D.", "age": 65, "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 630233, "fmt": "630.23k", "longFmt": "630,233"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 25579, "fmt": "25.58k", "longFmt": "25,579"}}, {"maxAge": 1, "name": "Mr. Brent  Warner", "age": 38, "title": "Pres of Gene Therapy", "yearBorn": 1984, "fiscalYear": 2022, "totalPay": {"raw": 835929, "fmt": "835.93k", "longFmt": "835,929"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 151938, "fmt": "151.94k", "longFmt": "151,938"}}, {"maxAge": 1, "name": "Ms. Johanna M. Mylet CPA", "age": 35, "title": "Chief Financial Officer", "yearBorn": 1987, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Loren  Wagner", "title": "Sr. VP of Global Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kristin  Martin", "title": "Chief People & Admin. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sarah  Thailing", "title": "Sr. Director of Corp. Communications & IR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Devon J. Shedlock Ph.D.", "title": "Chief Scientific Officer of Cell Therapy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lisa  Portale", "title": "Sr. VP of Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jeffrey  W. Winkelman J.D., Ph.D.", "title": "Sr. VP & Chief Patent Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}